Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

  • Track 1-1Alzheimer's disease pathophysiology and mechanisms
  • Track 1-2Genetics in Alzheimer's disease
  • Track 1-3Risk factors: head injury, depression and hypertention
  • Track 1-4Causes and preventions in Alzheimer's disease
  • Track 1-5Medication and diet for Alzheimer's disease
  • Track 1-6Symptoms of Alzheimer's disease
  • Track 1-7Brain imaging for Alzheimer's disease
  • Track 1-8Treatments in Alzheimer's
  • Track 1-9Cholinergic and amloid hypothesis in Alzheimer's
  • Track 1-10Alzheimer's disease associated complexities
  • Track 1-11Clinical Trials for Alzheimer's Disease
  • Track 1-12Recent advancements in Alzheimer's disease
  • Track 1-13Latest tests for detection of Alzheimer's disease
  • Track 2-1Vascular dementia treatment and management
  • Track 2-2Vascular dementia prevalence
  • Track 2-3Pathology of vascular dementia
  • Track 2-4Risk factors in vascular dementia
  • Track 2-5Strokes in vascular dementia
  • Track 2-6Subcortical vascular dementia
  • Track 2-7Stratagies for vascular dementia caregivers
  • Track 2-8Emerging therapies for vascular dementia
  • Track 3-1Stages of Lewy body dementia
  • Track 3-2Alpha- synuclein protein associated with Lewy body dementia
  • Track 3-3Lewy body dementia and Parkinson's disease
  • Track 3-4Physiotherapy affects in Lewy body dementia
  • Track 3-5Advancement in treatment of Lewy body dementia
  • Track 3-6Latest Lewy body dementia research
  • Track 4-1Frontotemporal dementia signs and diagnosis
  • Track 4-2Management of frontotemporal dementia
  • Track 4-3Spindle neurons
  • Track 4-4Primary progressive aphasia
  • Track 4-5Semantic dementia
  • Track 4-6Neuropsychological tests for frontotemporal dementia
  • Track 4-7Frontotemporal dementia and life expectancy
  • Track 5-1Medication in mixed dementia
  • Track 5-2Treatments for mixed dementia
  • Track 5-3Management of mixed dementia
  • Track 5-4Alzheimer's , Vascular and Lwey body dementia coexistance
  • Track 5-5Sleep and mixed dementia
  • Track 5-6Current research on Mixed Dementia
  • Track 6-1Age: factor for dementia related diseases
  • Track 6-2Mental illness
  • Track 6-3Hypertention
  • Track 6-4Genetics in Dementia
  • Track 6-5Hypothryroidism
  • Track 6-6Vitamin B12 deficiency
  • Track 6-7Neurosyphillis
  • Track 6-8Beta Amloid Accumulation
  • Track 6-9Perception and visual problems
  • Track 6-10Traumatic brain injury
  • Track 6-11Down syndrome
  • Track 6-12Mild cognitive impairment
  • Track 7-1Measuring proteins in blood
  • Track 7-2Mini mental state examination
  • Track 7-3Mental score test
  • Track 7-4Trail making test
  • Track 7-5Clock drawing test
  • Track 7-6Geriatric depression scale
  • Track 7-7Brain MRI scan
  • Track 7-8People with memory problems
  • Track 7-9Biomarkers for diagnosis
  • Track 8-1Reminiscence therapy
  • Track 8-2Psychological therapies
  • Track 8-3Dementia care advances through cloud technology
  • Track 8-4Natural treatments in dementia
  • Track 8-5Advances in person centred care in dementia
  • Track 8-6Home care thrapies
  • Track 9-1Cholinesterase inhibitors
  • Track 9-2Memantine
  • Track 9-3Medication for memory loss
  • Track 9-4Beta and gamma secretase inhibitors
  • Track 9-5Vitamin E and Omega-3-fatty acids
  • Track 9-6New drug development in dementia
  • Track 10-1Vaccine against beta-amloid
  • Track 10-2Beta-amloid polymerisation and inflammation inhibitor
  • Track 10-3Aggregation of Tau inhibition
  • Track 10-4Prevention trials
  • Track 10-5Advances in genetic research
  • Track 11-1Transgenic mice model
  • Track 11-2Rodent models
  • Track 11-3Transgenic and gene targeted models in dementia
  • Track 11-4Pharmacological validation in animal model of dementia
  • Track 11-5Validation of dementia models employing neuroimaging techniques
  • Track 11-6Drosophila melanogaster as a model organism for dementia
  • Track 11-7Zebrafish as a model organism for dementia
  • Track 11-8Lesion-induced vertebrate models of Alzheimer's dementia
  • Track 11-9AΒ infusion and related models of Alzheimer's dementia
  • Track 11-10APP-based transgenic models
  • Track 12-1End of life care
  • Track 12-2Ensuring safety and security of dementia patients
  • Track 12-3Exercise promoting mobility and special diet for dementia patients
  • Track 12-4Visial and acoustic stimulation
  • Track 12-5Communication affects over dementia patients
  • Track 12-6Emergency preparedness
  • Track 12-7Social enguagement
  • Track 12-8Art therapy- quality of life
  • Track 12-9Telecare
  • Track 13-1Dementia related behaviors
  • Track 13-2Diagnosis disclosure
  • Track 13-3Driving and dementia
  • Track 13-4Electronic tracking
  • Track 13-5Genetic testing in dementia
  • Track 13-6Placebo control
  • Track 13-7Protection of participants in research
  • Track 13-8Right to treatment
  • Track 14-1Person living with dementia
  • Track 14-2History of present illness in dementia patients
  • Track 14-3Coping with caring
  • Track 14-4HIV associated dementia case report
  • Track 14-5Vocalisation in dementia
  • Track 14-6Nonconvulsive seizures and dementia